• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by End-user
o Market segments
o Comparison by End-user
o Pharmaceutical and biotechnology companies – Market size and forecast 2019-2024
o Academic and research institutes – Market size and forecast 2019-2024
o CROs – Market size and forecast 2019-2024
o Market opportunity by End-user
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive scenario
o Vendor landscape
o Landscape disruption
o Industry risks
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Agilent Technologies Inc.
o AstraZeneca Plc
o Beckman Coulter Inc.
o Bio-Rad Laboratories Inc.
o Charles River Laboratories International Inc.
o Corning Inc.
o Danaher Corp.
o Eurofins Scientific SE
o F. Hoffmann-La Roche Ltd.
o Merck KGaA
o PerkinElmer Inc.
o Sartorius AG
o Tecan Group Ltd.
o Thermo Fisher Scientific Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: End user – Market share 2019-2024 (%)
• 22: Comparison by End user
• 23: Pharmaceutical and biotechnology companies – Market size and forecast 2019-2024 ($ million)
• 24: Pharmaceutical and biotechnology companies – Year-over-year growth 2019-2024 (%)
• 25: Academic and research institutes – Market size and forecast 2019-2024 ($ million)
• 26: Academic and research institutes – Year-over-year growth 2019-2024 (%)
• 27: CROs – Market size and forecast 2019-2024 ($ million)
• 28: CROs – Year-over-year growth 2019-2024 (%)
• 29: Market opportunity by End user
• 30: Customer landscape
• 31: Market share by geography 2019-2024 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2019-2024 ($ million)
• 34: North America – Year-over-year growth 2019-2024 (%)
• 35: Europe – Market size and forecast 2019-2024 ($ million)
• 36: Europe – Year-over-year growth 2019-2024 (%)
• 37: APAC – Market size and forecast 2019-2024 ($ million)
• 38: APAC – Year-over-year growth 2019-2024 (%)
• 39: ROW – Market size and forecast 2019-2024 ($ million)
• 40: ROW – Year-over-year growth 2019-2024 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Agilent Technologies Inc. – Overview
• 50: Agilent Technologies Inc. – Business segments
• 51: Agilent Technologies Inc. – Key offerings
• 52: Agilent Technologies Inc. – Key customers
• 53: Agilent Technologies Inc. – Segment focus
• 54: AstraZeneca Plc – Overview
• 55: AstraZeneca Plc – Product and service
• 56: AstraZeneca Plc – Key offerings
• 57: AstraZeneca Plc – Key customers
• 58: AstraZeneca Plc – Segment focus
• 59: Beckman Coulter Inc. – Overview
• 60: Beckman Coulter Inc. – Product and service
• 61: Beckman Coulter Inc. – Key offerings
• 62: Beckman Coulter Inc. – Key customers
• 63: Beckman Coulter Inc. – Segment focus
• 64: Becton, Dickinson and Co. – Overview
• 65: Becton, Dickinson and Co. – Business segments
• 66: Becton, Dickinson and Co. – Key offerings
• 67: Becton, Dickinson and Co. – Key customers
• 68: Becton, Dickinson and Co. – Segment focus
• 69: Bio-Rad Laboratories Inc. – Overview
• 70: Bio-Rad Laboratories Inc. – Business segments
• 71: Bio-Rad Laboratories Inc. – Key offerings
• 72: Bio-Rad Laboratories Inc. – Key customers
• 73: Bio-Rad Laboratories Inc. – Segment focus
• 74: Charles River Laboratories International Inc. – Overview
• 75: Charles River Laboratories International Inc. – Product and service
• 76: Charles River Laboratories International Inc. – Key offerings
• 77: Charles River Laboratories International Inc. – Key customers
• 78: Charles River Laboratories International Inc. – Segment focus
• 79: Corning Inc. – Overview
• 80: Corning Inc. – Business segments
• 81: Corning Inc. – Key offerings
• 82: Corning Inc. – Key customers
• 83: Corning Inc. – Segment focus
• 84: Danaher Corp. – Overview
• 85: Danaher Corp. – Business segments
• 86: Danaher Corp. – Key offerings
• 87: Danaher Corp. – Key customers
• 88: Danaher Corp. – Segment focus
• 89: Eurofins Scientific SE – Overview
• 90: Eurofins Scientific SE – Business segments
• 91: Eurofins Scientific SE – Key offerings
• 92: Eurofins Scientific SE – Key customers
• 93: Eurofins Scientific SE – Segment focus
• 94: F. Hoffmann-La Roche Ltd. – Overview
• 95: F. Hoffmann-La Roche Ltd. – Business segments
• 96: F. Hoffmann-La Roche Ltd. – Key offerings
• 97: F. Hoffmann-La Roche Ltd. – Key customers
• 98: F. Hoffmann-La Roche Ltd. – Segment focus
• 99: Merck KGaA – Overview
• 100: Merck KGaA – Business segments
• 101: Merck KGaA – Key offerings
• 102: Merck KGaA – Key customers
• 103: Merck KGaA – Segment focus
• 104: PerkinElmer Inc. – Overview
• 105: PerkinElmer Inc. – Business segments
• 106: PerkinElmer Inc. – Key offerings
• 107: PerkinElmer Inc. – Key customers
• 108: PerkinElmer Inc. – Segment focus
• 109: Sartorius AG – Overview
• 110: Sartorius AG – Business segments
• 111: Sartorius AG – Key offerings
• 112: Sartorius AG – Key customers
• 113: Sartorius AG – Segment focus
• 114: Tecan Group Ltd. – Overview
• 115: Tecan Group Ltd. – Business segments
• 116: Tecan Group Ltd. – Key offerings
• 117: Tecan Group Ltd. – Key customers
• 118: Tecan Group Ltd. – Segment focus
• 119: Thermo Fisher Scientific Inc. – Overview
• 120: Thermo Fisher Scientific Inc. – Business segments
• 121: Thermo Fisher Scientific Inc. – Key offerings
• 122: Thermo Fisher Scientific Inc. – Key customers
• 123: Thermo Fisher Scientific Inc. – Segment focus
• 124: Currency conversion rates for US$
• 125: Research Methodology
• 126: Validation techniques employed for market sizing
• 127: Information sources
• 128: List of abbreviations
【掲載企業】
Agilent Technologies Inc., AstraZeneca Plc, Beckman Coulter Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Corning Inc., Danaher Corp., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer Inc., Sartorius AG, Tecan Group Ltd., Thermo Fisher Scientific Inc.
【免責事項】
https://www.marketreport.jp/reports-disclaimer